- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-GLP1R/ GLP-1/ GLP-1-R monoclonal antibody
Anti-GLP1R/ GLP-1/ GLP-1-R antibody for FACS & in-vivo assay
Go to GLP1R/GLP1R products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T36075-Ab-1/ GM-Tg-hg-T36075-Ab-2 | Anti-Human GLP1R monoclonal antibody | Human |
| GM-Tg-rg-T36075-Ab-1/ GM-Tg-rg-T36075-Ab-2 | Anti-Rat GLP1R monoclonal antibody | Rat |
| GM-Tg-mg-T36075-Ab-1/ GM-Tg-mg-T36075-Ab-2 | Anti-Mouse GLP1R monoclonal antibody | Mouse |
| GM-Tg-cynog-T36075-Ab-1/ GM-Tg-cynog-T36075-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GLP1R monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T36075-Ab-1/ GM-Tg-felg-T36075-Ab-2 | Anti-Feline GLP1R monoclonal antibody | Feline |
| GM-Tg-cang-T36075-Ab-1/ GM-Tg-cang-T36075-Ab-2 | Anti-Canine GLP1R monoclonal antibody | Canine |
| GM-Tg-bovg-T36075-Ab-1/ GM-Tg-bovg-T36075-Ab-2 | Anti-Bovine GLP1R monoclonal antibody | Bovine |
| GM-Tg-equg-T36075-Ab-1/ GM-Tg-equg-T36075-Ab-2 | Anti-Equine GLP1R monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T36075-Ab-1/ GM-Tg-hg-T36075-Ab-2; GM-Tg-rg-T36075-Ab-1/ GM-Tg-rg-T36075-Ab-2; GM-Tg-mg-T36075-Ab-1/ GM-Tg-mg-T36075-Ab-2; GM-Tg-cynog-T36075-Ab-1/ GM-Tg-cynog-T36075-Ab-2; GM-Tg-felg-T36075-Ab-1/ GM-Tg-felg-T36075-Ab-2; GM-Tg-cang-T36075-Ab-1/ GM-Tg-cang-T36075-Ab-2; GM-Tg-bovg-T36075-Ab-1/ GM-Tg-bovg-T36075-Ab-2; GM-Tg-equg-T36075-Ab-1/ GM-Tg-equg-T36075-Ab-2 |
| Products Name | Anti-GLP1R monoclonal antibody |
| Format | mab |
| Target Name | GLP1R |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-GLP1R benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-INN-895 | |
| Biosimilar | GMP-Bios-INN-724 | Pre-Made Albiglutide Biosimilar, Peptide Protein Fusion targeting GLP1R: (Glp-1)2 Peptide-Albumin(Alb) Fusion Protein targetingGLP-1-R/GLP-1R |
| Biosimilar | GMP-Bios-INN-824 | |
| Biosimilar | GMP-Bios-INN-817 | |
| Biosimilar | GMP-Bios-INN-806 | Pre-Made Dulaglutide Biosimilar, Peptide Protein Fusion targeting GLP1R: (Glp-12) Peptide-Human Igg4 Fc Fusion Protein targeting GLP-1/GLP-1-R/GLP-1R |
| Target Antigen | Products Developing | Multi-species GLP1R/ GLP-1/ GLP-1-R VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLP003729 | human GLP1R Lentivirus plasmid |
| ORF Viral Vector | vGMLP003729 | human GLP1R Lentivirus particle |
| ORF Viral Vector | pGMLPm002809 | mouse Glp1r Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002809 | mouse Glp1r Lentivirus particle |
Target information
| Target ID | GM-T36075 |
| Target Name | GLP1R |
| Gene ID | 2740,14652,25051,719548,481778,101095495,517420,100065307 |
| Gene Symbol and Synonyms | Glip,GLP-1,GLP-1-R,GLP-1R,GLP1R,GLP1Rc,RATGL1RCP |
| Uniprot Accession | P43220,P32301 |
| Uniprot Entry Name | GLP1R_HUMAN,GLP1R_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | N/A |
| Gene Ensembl | ENSG00000112164 |
| Target Classification | GPCR |
The target: GLP1R, gene name: GLP1R, also named as GLP-1, GLP-1-R, GLP-1R. This gene encodes a 7-transmembrane protein that functions as a receptor for glucagon-like peptide 1 (GLP-1) hormone, which stimulates glucose-induced insulin secretion. This receptor, which functions at the cell surface, becomes internalized in response to GLP-1 and GLP-1 analogs, and it plays an important role in the signaling cascades leading to insulin secretion. It also displays neuroprotective effects in animal models. Polymorphisms in this gene are associated with diabetes. The protein is an important drug target for the treatment of type 2 diabetes and stroke. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Apr 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
